Daniel Pella, Viola Mechírová
Despite large improvement in diagnostic process and therapy remain arterial hypertension therapy still a major public health concern. In Slovakia, one of the reasons of this situation is lack of pharmacoepidemiological data about arterial hypertension. Scientific programme DELFÍN (for evaluation of therapeutic effect in not controlled hypertensive patients and hypertensive ones who did not tolerate current therapy) was designed with the aim to get pharmacoepidemiological data about arterial hypertension. Patients enrolled into the programme were subsequently treated with perindopril arginine in order to evaluate its efficacy and safety. Statistically significant decrease of systolic blood pressure from 157,47 ± 13,86 mmHg na 135,11 ± 11,24 mmHg (p < 0,00001) was found in the group of 2016 patients after 3 months of therapy and diastolic blood pressure from 95,94 ± 7,66 mmHg to 83,15 ± 6,81 mmHg (p < 0,00001). Interesting finding was significant reduction of heart rate (showing the role of sympathetic nervous system in the pathogenesis of arterial hypertension) from 76,40 ± 8,81/min. to 73,07 ± 6,52/min. (p < 0,00001). Adverse effects (not serious) were observed only in 2 % of treated patients which confirm together with excellent compliance to therapy significant role of perindopril in modern arterial hypertension management.